You are here

Article Text

Article menu

Download PDFPDF

Poster Presentation
Anti-EGFR targeted monoclonal antibody isotype influences anti-tumor immunity in head and neck cancer patients
  1. Sumita Trivedi1,
  2. Raghvendra M Srivastava1,
  3. Fernando Concha-Benavente2,
  4. Tatiana M Garcia-Bates1,
  5. Jing Li1 and
  6. Robert L Ferris1
  1. Aff1 grid.21925.3d0000000419369000University of Pittsburgh Cancer Institute Pittsburgh PA USA
  2. Aff2 grid.21925.3d0000000419369000Department of ImmunologyUniversity of Pittsburgh Pittsburgh PA USA

https://doi.org/10.1186/2051-1426-3-S2-P316

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meeting abstracts

    EGFR is frequently overexpressed on several cancers, and two targeted antibodies are FDA approved but differ by isotype. Cetuximab (IgG1 isotype) has been shown to be effective at both inhibiting downstream signaling of EGFR and activating anti-tumor, cellular immune mechanisms. While panitumumab (IgG2 isotype) can inhibit downstream EGFR signaling similar to cetuximab, panitumumab might also induce antibody-dependent cell cytotoxicity (ADCC) or adaptive immunity. We sought to investigate the cellular immunity specifically activated by cetuximab or panitumumab showing that both mAb primarily activate NK cells, although cetuximab was significantly more potent than panitumumab. We also observed that although panitumumab may activate monocytes through the CD32 (FcγRIIa) receptor, neither mAb activated monocytes sufficiently to mediate ADCC. Cetuximab enhanced DC maturation to a greater extent than panitumumab, corresponding with improved cross presentation of tumor antigen by cetuximab compared with panitumumab. Indeed, improved adaptive immune responses with increased EGFR-specific cytotoxic CD8+ T cells were present in patients treated with cetuximab compared to those treated with panitumumab. These results suggest that although panitumumab effectively inhibits EGFR signaling to a similar extent as cetuximab, it is less effective at mediating anti-tumor, cellular immune mechanisms which may be crucial for effective therapy for HNSCC.